Cargando…
Treatment of Prostate Cancer with CD46-targeted (225)Ac Alpha Particle Radioimmunotherapy
PURPOSE: Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression in prostate cancer and developed an antibody–drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46...
Autores principales: | Bidkar, Anil P., Wang, Sinan, Bobba, Kondapa Naidu, Chan, Emily, Bidlingmaier, Scott, Egusa, Emily A., Peter, Robin, Ali, Umama, Meher, Niranjan, Wadhwa, Anju, Dhrona, Suchi, Dasari, Chandrashekhar, Beckford-Vera, Denis, Su, Yang, Tang, Ryan, Zhang, Li, He, Jiang, Wilson, David M., Aggarwal, Rahul, VanBrocklin, Henry F., Seo, Youngho, Chou, Jonathan, Liu, Bin, Flavell, Robert R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183825/ https://www.ncbi.nlm.nih.gov/pubmed/36917693 http://dx.doi.org/10.1158/1078-0432.CCR-22-3291 |
Ejemplares similares
-
Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac α-Radiotherapeutics
por: Bobba, Kondapa Naidu, et al.
Publicado: (2023) -
Prostate-Specific
Membrane Antigen Targeted Deep Tumor
Penetration of Polymer Nanocarriers
por: Meher, Niranjan, et al.
Publicado: (2022) -
PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
por: Meher, Niranjan, et al.
Publicado: (2023) -
Covalent Proteins
as Targeted Radionuclide Therapies
Enhance Antitumor Effects
por: Klauser, Paul C., et al.
Publicado: (2023) -
CD46 targeted (212)Pb alpha particle radioimmunotherapy for prostate cancer treatment
por: Li, Jun, et al.
Publicado: (2023)